#	Pagina
attuale pagina	/open-h2020/projects/226464/index.html

Opendata, web and dolomites

TherVacB SIGNED

THERVACB: A THERAPEUTIC VACCINE TO CURE HEPATITIS B

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

TherVacB project word cloud

Explore the words cloud of the TherVacB project. It provides you a very rough idea of what is the project "TherVacB" about.

efficacy clinical translational lacking breaking particulate secured core proving therapy infection gt host resistance patients ethical lacks recruitment approved capacity immunology interdisciplinary components occurrence thervacb tackle options vector realized expressing therapeutic social virology polymerase diagnostic adjuvanted track cell antigens cells registry monitoring prepare interaction innovative 95 perform biomarkers heterologous proof human scheme treatment obtain stigmatize arm activate neutralizing gmp hepatitis excellent experts tolerance preclinical record proven tanzania patient immune care ip induce trial immunity virus cure first mva models africa hbv local chronic quantify vaccine boosted protected media found burden safety jointly ib spontaneous resolution boost vaccination iia infectious inducing protein center of form clinically prime antibodies worldwide injections carries diseases tend empirical predict

Project "TherVacB" data sheet

The following table provides information about the project.

Coordinator	HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH Organization address address: INGOLSTADTER LANDSTRASSE 1 city: NEUHERBERG postcode: 85764 website: www.helmholtz-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	10˙425˙686 €
EC max contribution	10˙425˙686 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2019-Two-Stage-RTD
Funding Scheme	RIA
Starting year	2020
Duration (year-month-day)	from 2020-01-01 to 2024-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH Organization address address: INGOLSTADTER LANDSTRASSE 1 city: NEUHERBERG postcode: 85764 website: www.helmholtz-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (NEUHERBERG)	coordinator	4˙049˙761.00
2	KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN Organization address address: ISMANINGER STRASSE 22 city: MUENCHEN postcode: 81675 website: http://www.med.tu.muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	1˙394˙787.00
3	CTC NORTH GMBH & CO KG CTC NORTH GMBH & CO KG Organization address address: MARTINISTRASSE 64 city: HAMBURG postcode: 20251 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	1˙113˙125.00
4	AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA Organization address address: VIA GRAMSCI 14 city: PARMA postcode: 43100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PARMA)	participant	714˙893.00
5	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	675˙380.00
6	UNIVERSITY COLLEGE LONDON UNIVERSITY COLLEGE LONDON Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	536˙023.00
7	NATIONAL INSTITUTE FOR MEDICAL RESEARCH NATIONAL INSTITUTE FOR MEDICAL RESEARCH Organization address address: SOKOINE LUTHULI DRIVE OCEAN ROAD city: DAR ES SALAAM postcode: 255 website: www.nimr.or.tz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	TZ (DAR ES SALAAM)	participant	489˙287.00
8	ARTTIC ARTTIC Organization address address: RUE DU DESSOUS DES BERGES 58A city: PARIS postcode: 75013 website: www.arttic.eu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	272˙746.00
9	UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF Organization address address: Martinistrasse 52 city: HAMBURG postcode: 20251 website: www.uke.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	209˙350.00
10	TECHNISCHE UNIVERSITAET MUENCHEN TECHNISCHE UNIVERSITAET MUENCHEN Organization address address: Arcisstrasse 21 city: MUENCHEN postcode: 80333 website: www.tu-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	191˙556.00
11	FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA Organization address address: CARRER ROSSELLO 149 city: BARCELONA postcode: 8036 website: www.fundacioclinic.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	153˙750.00
12	HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Organization address address: INHOFFENSTRASSE 7 city: BRAUNSCHWEIG postcode: 38124 website: www.helmholtz-hzi.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BRAUNSCHWEIG)	participant	146˙500.00
13	UNIVERSITAET LEIPZIG UNIVERSITAET LEIPZIG Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 website: www.uni-Ieipzig.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LEIPZIG)	participant	142˙900.00
14	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	131˙125.00
15	BARTS AND THE LONDON NHS TRUST BARTS AND THE LONDON NHS TRUST Organization address address: PRESCOT STREET 9 city: LONDON postcode: E1 8PR website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	104˙500.00
16	ROYAL FREE LONDON NHS FOUNDATION TRUST ROYAL FREE LONDON NHS FOUNDATION TRUST Organization address address: POND STREET HAMPSTEAD city: LONDON postcode: NW3 2QG website: http://www.royalfree.nhs.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	100˙000.00

Map

Project objective

Experts in virology, immunology and clinical hepatitis B patient care with an excellent research and translational track record in hepatitis B virus (HBV)-host interaction form the interdisciplinary TherVacB consortium. They jointly tackle the major challenges in HBV therapy – the virus’s resistance to cure. TherVacB aims at breaking immune tolerance in chronic HBV infection and achieving HBV cure. Occurrence of neutralizing antibodies and HBV-specific T cell responses characterize spontaneous resolution of HBV infection that are lacking in chronic infection. We will use our IP-protected heterologous prime-boost therapeutic vaccination scheme with proven efficacy in preclinical models of hepatitis B to target and activate B and T cell responses. Two protein prime injections with clinically approved, adjuvanted particulate HBV S and core protein antigens shall induce neutralizing antibodies and prime T cells that are boosted with an MVA vector expressing HBV core, S, L and polymerase antigens covering >95% of HBV found worldwide. Having secured significant funding and partnerships to obtain GMP-produced vaccine components and to prepare a first-in-human application, TherVacB aims at a clinical proof-of-concept of the therapeutic hepatitis B vaccine in patients with chronic hepatitis B. The consortium will establish a patient registry and perform a multi-center phase Ib/IIa clinical trial that aims at proving safety of the therapeutic vaccine and inducing immune control of chronic HBV infection. One study arm will be realized in Tanzania to build up local capacity, because Africa carries a large burden of HBV infection but lacks diagnostic and therapeutic options. An innovative immune monitoring will quantify HBV-specific immunity and define novel biomarkers to predict treatment response. Finally an ethical and an empirical study will evaluate the recruitment of patients by social media which is very effective for infectious diseases that tend to stigmatize patients

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERVACB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERVACB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISLET (2020)

Advancing Innovative Stem Cell-based Therapy for Diabetes in Europe

Read More

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More

VANGUARD (2020)

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Read More